Clinical trials
Recurrent Oral Cavity Squamous Cell Carcinoma clinical trials
Below are recruiting recurrent oral cavity squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 84 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05808920Recruiting
Salvage surgery study for recurrent head and neck skin-cell cancer
This study looks at how well people do after “salvage” surgery (planned surgery after prior treatment) for recurrent or residual squamous cell cancer in the head and neck. It may help doctors understand which patients benefit most, including how this surgery affects survival and day-to-day function.
DerbyAges 18 years+ - NCT06016920RecruitingPhase 1/Phase 2
HPV16 vaccine plus Keytruda for oropharyngeal cancer
This trial tests a new vaccine (VB10.16) combined with the immunotherapy Keytruda (pembrolizumab) for people with HPV16-positive oropharyngeal cancer that has spread or come back. The goal is to see if the combination helps shrink tumors or slow cancer growth.
OlomoucAges 18 years+ - NCT06030440RecruitingPhase 2/Phase 3
Lowering radiation after head and neck cancer surgery
This study tests whether giving a lower dose of radiation after surgery for head and neck cancer is as safe and effective as the standard dose. It aims to reduce side effects while still preventing the cancer from coming back.
Erlangen, BavariaAges 18 years+ - NCT06056336RecruitingPhase 2
Perioperative tislelizumab plus chemo for esophageal cancer
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06061705Recruiting
Finding markers in patients with head and neck cancer on immunotherapy
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
ParisAges 18 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Birmingham, AlabamaAges 18–130 - NCT06323460RecruitingPhase 2
Less Radiation for HPV Throat Cancer Guided by a Blood Test
This study tests a way to use less radiation for HPV-related throat cancer. Doctors will adjust your treatment based on a simple blood test that tracks cancer DNA, so you may get only the treatment you need.
Columbus, OhioAges 18 years+ - NCT06353685RecruitingPhase 2
Less radiation after surgery for oral cancer with good response
This trial is testing whether giving less radiation after surgery is safe and effective for people with oral cancer whose surgery results were very good (no cancer cells or very few left). It aims to reduce side effects while still preventing cancer from coming back.
GuangzhouAges 18–80 - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT06489197RecruitingPhase 2
AK112 plus chemo for advanced esophageal cancer
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT06627270RecruitingPhase 2
Antibiotics before surgery for oral cancer
This trial tests if taking antibiotics and using a mouth rinse before surgery can help treat oral cancer by targeting bacteria inside the tumor. It is for people with a new diagnosis of oral cancer who are scheduled for surgery.
Cleveland, OhioAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT07460765RecruitingPhase 1
Nivolumab with a special dye for head and neck cancer surgery
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
Nashville, TennesseeAges 18 years+ - NCT06736379RecruitingPhase 1
RNA Therapy Injections for Head and Neck Cancer
This trial tests a new type of immunotherapy made of self-amplifying RNA (saRNA) that produces a protein called IL-12. It's injected directly into head and neck tumors to help your immune system fight the cancer. The study is for people whose cancer has not responded well to standard treatments or who are having surgery to remove their tumor.
Stanford, CaliforniaAges 18 years+ - NCT06856213RecruitingPhase 2
Cetuximab with or without weekly paclitaxel for head and neck cancer
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT06857279RecruitingPhase 2
Testing HLX43 for advanced head and neck cancer
This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–75 - NCT06868433RecruitingPhase 1
TMV vaccine alone or with pembrolizumab for advanced HNSCC
This trial tests a vaccine made from your own tumor to help your immune system fight head and neck cancer that has returned or spread. It is given alone or with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors or slow progression.
Atlanta, GeorgiaAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT06912087RecruitingPhase 1
Finding the right dose of a new combo for head and neck cancer
This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.
Chicago, IllinoisAges 18 years+ - NCT06915454Recruiting
Better imaging during cancer surgery
This trial tests a high-resolution PET-CT scan done during surgery to help surgeons see exactly where the cancer ends. It may help make sure all cancer is removed while saving healthy tissue.
Nashville, TennesseeAges 18 years+
Hear when a new Recurrent Oral Cavity Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent oral cavity squamous cell carcinoma?
- Yes. Clin2 currently lists 84 recruiting recurrent oral cavity squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent oral cavity squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent oral cavity squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Recurrent Oral Cavity Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Metastatic Oral Cavity Squamous Cell Carcinoma
- Oral Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Recurrent Hypopharyngeal Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.